Anuh Pharma (BOM:506260) ROCE %: 17.64% (As of Mar. 2026)


BOM:506260 Anuh Pharma Ltd BOM:506260
84 GF Score
Price ₹80.21
GF Value ₹105.36
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Anuh Pharma ROCE %?

Anuh Pharma BOM:506260 -1.57% 84 ROCE % is 17.64% as of Mar. 2026. GuruFocus rates BOM:506260 with a GF Score™ of 84/100 and a GF Value™ of ₹105.36 (Modestly Undervalued). The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Anuh Pharma's annualized ROCE % for the quarter that ended in Mar. 2026 was 17.64%.

Anuh Pharma  (BOM:506260) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Anuh Pharma ROCE % Related Terms

Anuh Pharma ROCE % Historical Data

* Premium members only.

The historical data trend for Anuh Pharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anuh Pharma ROCE % Chart

Anuh Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.58 20.74 29.32 19.84 16.03

Anuh Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.11 13.61 12.16 21.78 17.64
BOM:506260
84GF Score
Anuh Pharma Ltd BOM:506260
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anuh Pharma ROCE % Calculation

Anuh Pharma's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=546.937/( ( (5066.277 - 1785.136) + (5573.679 - 2030.033) )/ 2 )
=546.937/( (3281.141+3543.646)/ 2 )
=546.937/3412.3935
=16.03 %

Anuh Pharma's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=625.012/( ( (0 - 0) + (5573.679 - 2030.033) )/ 1 )
=625.012/( ( 0 + 3543.646 )/ 1 )
=625.012/3543.646
=17.64 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 17.64% mean?
Anuh Pharma (BOM:506260) has a ROCE % of 17.64% as of Mar. 2026.
Is Anuh Pharma's ROCE % too high?
Anuh Pharma's current ROCE % is 17.64%. The Drug Manufacturers industry median ROCE % is 7.02. Anuh Pharma's value of 17.64% is 151.3% above this industry median. Overall, Anuh Pharma has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Anuh Pharma's ROCE % compare to ZTS and UTHR?
Anuh Pharma's ROCE % of 17.64% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.02. Anuh Pharma's value of 17.64% is 151.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.02, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anuh Pharma's current ROCE % of 17.64% is 151.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anuh Pharma's current ROCE % is 17.64%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anuh Pharma stock overvalued right now?
Based on GuruFocus' analysis, Anuh Pharma (BOM:506260) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹105.36, compared to a current price of ₹80.21 — trading 23.9% below its estimated fair value. The current ROCE % is 17.64% and 151.3% above the Drug Manufacturers industry median of 7.02. Anuh Pharma's overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Anuh Pharma (BOM:506260), the current ROCE % is 17.64% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Anuh Pharma (BOM:506260) Overvalued in 2026?

Based on GuruFocus' analysis, Anuh Pharma stock appears to be undervalued. The current stock price of ₹80.21 is trading 23.9% below its estimated GF Value™ of ₹105.36. GuruFocus considers Anuh Pharma to be Modestly Undervalued.

Key valuation signals for BOM:506260:

  • ROCE %: 17.64%
  • GF Value™: ₹105.36 vs. price of ₹80.21 (23.9% below fair value)
  • GF Score™: 84/100 with 1 warning sign
  • Industry Position: 151.3% above the Drug Manufacturers median

No single metric tells the full story. See the BOM:506260 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Anuh Pharma Business Description

Other Exchanges ANUHPHR:India
Address Dr. Annie Besant Road, North Wing, 3-A, Shiv Sagar Estate, Worli, Mumbai, MH, IND, 400 018
Anuh Pharma Ltd is engaged in the business of manufacturing and selling of Bulk drugs and chemicals. Geographically, it derives a majority of revenue from India. Its product categories include macrolides, anti-TB, anti-malarial, anti-bacterial, anti-hypertension, expectorant, quinolones, and others. The company generates revenue from the sale of Branded Prescription drugs, Over-the-Counter (OTC) drugs and Generic Prescription drugs.
84GF Score

Get the complete analysis for BOM:506260

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹80.21
Price
₹105.36
GF Value